Cardiovascular disease remains the leading cause of mortality worldwide, necessitating deeper insights into its molecular underpinnings beyond genetic predisposition. Epigenetic modifications, ...

Explore how proteomics supports pre-symptomatic disease detection, from mass spectrometry advances to multi-omics models and clinical validation challenges.

In 2026, artificial intelligence (AI) systems are deployed at scale to support clinical decision-making. Algorithms detect cardiac arrhythmias from ECGs, classify skin lesions from photographs and ...

Atherosclerosis represents a chronic inflammatory disease characterized by the accumulation of lipid-laden macrophage foam cells within arterial ...

Concentration of plastics was 2.5 times higher in cancerous tissue versus benign tissue ...

Background Severe aortic stenosis (AS) is commonly associated with advanced cardiac damage, including right ventricular dysfunction (RVD), pulmonary hypertension (PH) and tricuspid regurgitation (TR), ...

This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...

Background Psoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular ...

Anticoagulation is a critical component in the treatment of cardiovascular diseases. Large randomised controlled trials have ...

Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...

Cerebral amyloid angiopathy (CAA) is a condition where protein (called amyloid) builds up in the brain, making blood vessels weak. People with CAA are four times more likely to develop dementia within ...

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...